AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

PCVX · NASDAQ · Biotechnology

Vaxcyte (PCVX)

Developer of high-valency bacterial vaccine candidates using cell-free protein synthesis.

$56.15

vs last close−2.87 (−4.86%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Cost of revenue	0	0	0	0	0	0	0	5	0	−5	6	0
Gross profit	0	0	0	0	0	0	0	−5	0	5	−6	0
	113	197	114	153	140	162	181	221	242	279	340	303
Research & development	97	104	95	132	117	134	148	194	210	242	313	268
	16	18	20	21	23	29	33	32	32	32	33	35
General & administrative	16	18	20	21	23	29	33	32	32	32	33	35
Other expenses	0	75	0	0	0	0	0	−5	0	5	−6	0
Operating income	−113	−197	−114	−153	−140	−162	−181	−226	−242	−274	−346	−303
	20	16	19	24	37	25	40	60	30	28	25	18
Interest income	18	18	22	24	28	36	33	31	29	26	27	26
Other non-operating income	−2	−16	−19	−24	0	−105	−40	−60	−30	−28	−25	−7
Income before tax	−93	−181	−95	−129	−103	−137	−141	−167	−213	−247	−321	−284
Net income from continuing operations	−93	−181	−95	−129	−103	−137	−141	−167	−213	−247	−321	−284
Net income	−93	−181	−95	−129	−103	−137	−141	−167	−213	−247	−321	−284
EPS, basic	−$0.91	−$1.73	−$0.85	−$1.10	−$0.83	−$1.12	−$1.04	−$1.22	−$1.56	−$1.81	−$2.30	−$1.97
EPS, diluted	−$0.91	−$1.73	−$0.85	−$1.10	−$0.83	−$1.12	−$1.04	−$1.22	−$1.56	−$1.81	−$2.30	−$1.97
Weighted average shares, basic	102	104	112	117	124	123	136	136	136	136	140	144
Weighted average shares, diluted	102	104	112	117	124	123	136	136	136	136	140	144
EBITDA	−109	−178	−92	−125	−135	−53	−136	−162	−210	−235	−315	−292
Depreciation & amortization	2	3	3	3	4	5	5	5	3	12	6	3
EBIT	−111	−181	−95	−129	−140	−57	−141	−167	−213	−247	−321	−295